LILLYDIRECT
"LILLYDIRECT" is a word mark owned by Eli Lilly and Company, filed at the CIPO on September 28, 2023. It is registered and covers classes 5, 9 and 44.
- Status
- Registered
- Since April 22, 2026
- Filed
- September 28, 2023
- Registered
- April 22, 2026
- Expires
- April 22, 2036
- Application no.
- 2284174
- Registration no.
- TMA1405233
- Office
- CIPO
- Canadian Intellectual Property Office
- Mark type
- Word mark
- 3 classes
Who owns LILLYDIRECT
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Eli Lilly and Company
LLY · United States
Representative
Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
What the mark covers
The products and services LILLYDIRECT is filed for, grouped by Nice class.
House mark for a full line of pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone diseases and disorders and musculoskeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, eczema, acne, roseacea, ichthyosis, vitiligo, uticaria and alopecia areata, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, diabetes, dyslipidemia, endocrine diseases and disorders, namely, growth and thyroid disorders, diabetes and obesity, and hormonal diseases, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases, inflammatory muscle diseases and disorders and pharmaceutical preparations for the treatment of inflammation, namely anti-inflammatory preparations, pharmaceutical preparations for the treatment of kidney diseases and disorders, liver diseases and disorders, lupus, mental health disorders, metabolic diseases and disorders, namely, diabetes, gout, arthritis and anemia, obesity, hyperlipidemia, insulin resistance and metabolic syndrome, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, namely, Alzheimer's, Huntington's disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, amyotrophic lateral sclerosis (ALS), encephalitis, meningitis, muscular dystrophy, myasthenia gravis, dystonia, epilepsy, seizures, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases.
Downloadable software that allows users to access and receive telemedicine services and that allows telemedicine services providers to perform telemedicine services; downloadable software for telehealth and telemedicine operations, namely, computer software for accessing medical and health information, computer software to monitor pharmaceutical treatment plans, track patient compliance and verify treatment outcomes of prescription medication, software applications for accessing medical and health information, computer software allowing users to consult with a pharmacist in the field of pharmaceuticals and medications; downloadable computer software for prescribing, ordering, filling, managing and providing information regarding prescription usage, dosage and directions for prescription medications; downloadable software for enabling patients to review details about medications and receive automated warnings of potential adverse interactions of medications; downloadable software for enabling patients to request, receive, track shipment of, and manage prescriptions and orders for pharmaceuticals; downloadable software for enabling patients to access general medical, health, and wellness information and advice.
Healthcare services, namely medical care and analysis services in the field of patient treatment; medical services for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone diseases and disorders and musculoskeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, eczema, acne, roseacea, ichthyosis, vitiligo, uticaria and alopecia areata, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, diabetes, dyslipidemia, endocrine diseases and disorders, namely, growth and thyroid disorders, diabetes and obesity, and hormonal diseases, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases, inflammatory muscle diseases and disorders and pharmaceutical preparations for the treatment of inflammation, namely anti-inflammatory preparations, pharmaceutical preparations for the treatment of kidney diseases and disorders, liver diseases and disorders, lupus, mental health disorders, metabolic diseases and disorders, namely, diabetes, gout, arthritis and anemia, obesity, hyperlipidemia, insulin resistance and metabolic syndrome, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, namely, Alzheimer's, Huntington's disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, amyotrophic lateral sclerosis (ALS), encephalitis, meningitis, muscular dystrophy, myasthenia gravis, dystonia, epilepsy, seizures, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases; arranging and providing medical information services relating to pharmaceuticals, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals.; Telemedicine services
What has happened so far
Steps recorded by the CIPO, newest first.
- Registered
- Registration Pending
- Advertised; Vol.73 Issue 3719
- Approval Notice Sent; APPROVED BY PROGRAM EX200M1
- Approved; APPROVED BY PROGRAM EX200M1
- Examiner's First Report
- Search Recorded
- Pre-Assessment Letter Sent; Multiple Reasons
- Formalized
- Created
1 earlier step on the official record.
About LILLYDIRECT
Who owns the trademark "LILLYDIRECT"?
The CIPO trademark "LILLYDIRECT" (application 2284174) is owned by Eli Lilly and Company.
What is the status of "LILLYDIRECT"?
Its status at the CIPO is: registered.
When was "LILLYDIRECT" registered?
It was registered on April 22, 2026 and is due to expire on April 22, 2036.
Get this data via the API
Everything on this page comes from the Signa API. Pull LILLYDIRECT and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019deb3a-31d1-7321-876d-34ae6fc1b7f7
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019deb3a-31d1-7321-876d-34ae6fc1b7f7",
"object": "trademark",
"mark_text": "LILLYDIRECT",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "CA",
"application_number": "2284174",
"filing_date": "2023-09-28",
"nice_classes": [
5,
9,
44
],
"owners": [
{
"name": "ELI LILLY AND COMPANY",
"entity_id": "ent_019f286c-97ee-774b-84b5-7d5dc09e0b99"
}
]
}